Alessandro Di Federico, Medical Oncologist and Ph.D. student at the University of Bologna, shared a post on X about a paper published in AACR Journals:
“Not all oncogenes are the same. Patients w/ MET-driven NSCLC are frequently smokers and have often high PD-L1. This important study led by Federica Pecci, Xiuning Le identified factors to tailor treatment sequencing (ICI and MET-TKIs) in this population.”
Title: First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Authors: Federica Pecci, Hui Li, Alessandro Di Federico, Jia Wu, Hong Chen, Eleonora Gariazzo, Francesco Mantuano, Edoardo Garbo, Mihaela Aldea, Valentina Santo, Don Gibbons, Hai Tran, Francesco Paoloni, Guilherme Rossato de Almeida, Giulio Metro, Andrea De Giglio, Francesco Gelsomino, Xinan Wang, Marcello Tiseo, Julia Rotow, Andrea Ardizzoni, J. Jack Lee, Mark M. Awad, Alfredo Addeo, Lingzhi Hong, Marcelo V. Negrao, Pasi A. Janne, John V. Heymach, Jianjun Zhang, Biagio Ricciuti, Xiuning Le
Read the full article.
More posts featuring Alessandro Di Federico on OncoDaily.